ES2565675T3 - Sistema marcador celular/ligando donde el marcador es de tipo Eph, material celular que comprende dicho sistema, proceso de preparación y utilización proangiogénica - Google Patents

Sistema marcador celular/ligando donde el marcador es de tipo Eph, material celular que comprende dicho sistema, proceso de preparación y utilización proangiogénica Download PDF

Info

Publication number
ES2565675T3
ES2565675T3 ES06794234.2T ES06794234T ES2565675T3 ES 2565675 T3 ES2565675 T3 ES 2565675T3 ES 06794234 T ES06794234 T ES 06794234T ES 2565675 T3 ES2565675 T3 ES 2565675T3
Authority
ES
Spain
Prior art keywords
marker
efrin
ligand
ephb4
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06794234.2T
Other languages
English (en)
Spanish (es)
Inventor
Philippe Foubert
Jean-Sébastien SILVESTRE
Sophie Le Ricousse-Roussanne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Diderot Paris 7
IVS Institut des Vaisseaux et du Sang
Original Assignee
Universite Paris Diderot Paris 7
IVS Institut des Vaisseaux et du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Diderot Paris 7, IVS Institut des Vaisseaux et du Sang filed Critical Universite Paris Diderot Paris 7
Application granted granted Critical
Publication of ES2565675T3 publication Critical patent/ES2565675T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES06794234.2T 2005-07-27 2006-07-27 Sistema marcador celular/ligando donde el marcador es de tipo Eph, material celular que comprende dicho sistema, proceso de preparación y utilización proangiogénica Active ES2565675T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0508029 2005-07-27
FR0508029A FR2889200B1 (fr) 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
PCT/FR2006/001837 WO2007012764A2 (fr) 2005-07-27 2006-07-27 Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique

Publications (1)

Publication Number Publication Date
ES2565675T3 true ES2565675T3 (es) 2016-04-06

Family

ID=36353668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06794234.2T Active ES2565675T3 (es) 2005-07-27 2006-07-27 Sistema marcador celular/ligando donde el marcador es de tipo Eph, material celular que comprende dicho sistema, proceso de preparación y utilización proangiogénica

Country Status (11)

Country Link
US (1) US8338169B2 (enExample)
EP (1) EP1913130B1 (enExample)
JP (4) JP5755829B2 (enExample)
CN (1) CN101273123B (enExample)
AU (1) AU2006273928B2 (enExample)
CA (1) CA2616712C (enExample)
DK (1) DK1913130T3 (enExample)
ES (1) ES2565675T3 (enExample)
FR (1) FR2889200B1 (enExample)
IL (1) IL188938A (enExample)
WO (1) WO2007012764A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
AU2008223817A1 (en) 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4240635C2 (de) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
WO2000031124A2 (en) 1998-11-20 2000-06-02 Mount Sinai Hospital Peptides that modulate the interaction of b class ephrins and pdz domains
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
AU2002243623A1 (en) 2001-01-26 2002-08-06 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
AU2002311792A1 (en) 2001-03-30 2002-10-15 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
US20050049194A1 (en) 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
AU2003232457A1 (en) 2002-05-29 2003-12-19 Curagen Corporation Compositions and methods of use for an ephrin rreceptor
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
AU2004220459B2 (en) 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
WO2007012764A2 (fr) 2007-02-01
JP6235639B2 (ja) 2017-11-22
CN101273123B (zh) 2013-06-26
CN101273123A (zh) 2008-09-24
IL188938A0 (en) 2008-04-13
EP1913130B1 (fr) 2015-12-23
JP2017169590A (ja) 2017-09-28
JP5755829B2 (ja) 2015-07-29
AU2006273928B2 (en) 2012-02-16
IL188938A (en) 2014-09-30
AU2006273928A1 (en) 2007-02-01
JP2009505638A (ja) 2009-02-12
DK1913130T3 (en) 2016-03-29
US8338169B2 (en) 2012-12-25
FR2889200B1 (fr) 2008-01-04
JP5981525B2 (ja) 2016-08-31
FR2889200A1 (fr) 2007-02-02
EP1913130A2 (fr) 2008-04-23
CA2616712A1 (fr) 2007-02-01
JP2016127863A (ja) 2016-07-14
CA2616712C (fr) 2015-11-17
WO2007012764A3 (fr) 2007-05-31
US20090123431A1 (en) 2009-05-14
JP2015061536A (ja) 2015-04-02

Similar Documents

Publication Publication Date Title
Wang et al. HIF-1α overexpression in mesenchymal stem cell-derived exosome-encapsulated arginine-glycine-aspartate (RGD) hydrogels boost therapeutic efficacy of cardiac repair after myocardial infarction
Robinson et al. A novel platelet lysate hydrogel for endothelial cell and mesenchymal stem cell-directed neovascularization
Lo et al. Cell surface glycoengineering improves selectin-mediated adhesion of mesenchymal stem cells (MSCs) and cardiosphere-derived cells (CDCs): pilot validation in porcine ischemia-reperfusion model
ES2378165T3 (es) Utilización de células procedentes del tejido adiposo para inducir a la formación de una red vascular funcional
Yang et al. Combined transplantation of adipose tissue‐derived stem cells and endothelial progenitor cells improve diabetic erectile dysfunction in a rat model
JP2021118728A (ja) 線維芽細胞の製造方法及びｇ−ｃｓｆ陽性線維芽細胞集団
ES2565675T3 (es) Sistema marcador celular/ligando donde el marcador es de tipo Eph, material celular que comprende dicho sistema, proceso de preparación y utilización proangiogénica
CN101600446B (zh) 用作血管再形成刺激剂的细胞制备物
CN106459902B (zh) 组织再生促进剂
JP7193849B2 (ja) 虚血組織に集積するエクソソームおよびその製造方法
ES2366701T3 (es) Técnicas in vitro para su uso con células madre.
Jasiewicz Utilizing Leucine Zippers to Mediate Improved Carrier Accumulation and Retention at the Site of Myocardial Infarction
RU2372354C1 (ru) Слитый белок, имеющий активность ингибитора ангиогенеза
Gao Stem Cell and Drug Delivery Systems for Promoting Angiogenesis and Myogenesis in Ischemic Limbs
WO2025100511A1 (ja) 融合ペプチド
Wang et al. Mechanical energy-charged navigating pump repair natural vascular scaffolds to reverse osteoporosis
EP4561548A1 (en) Methods and compositions for using leucine zippers for crosslinking of cells and drug carriers
JP2010083808A (ja) 新規ペプチド誘導体を含む造血系細胞増殖促進剤
Thum et al. Recent patents on cardiovascular stem cells
WO2005097170A1 (ja) 血管新生促進剤および血管新生療法